UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 4.

Eggermont, A M M; Suciu, S; Testori, A; Kruit, W H; Marsden, J; Punt, C J; Santinami, M; Salès, F; Schadendorf, D; Patel, P; Dummer, R; Robert, C; Keilholz, U; Yver, A; Spatz, A (2012). Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. European Journal of Cancer, 48(2):218-225.

Chapman, P B; Hauschild, A; Robert, C; Haanen, J B; Ascierto, P; Larkin, J; Dummer, R; Garbe, C; Testori, A; Maio, M; Hogg, D; Lorigan, P; Lebbe, C; Jouary, T; Schadendorf, D; Ribas, A; O'Day, S J; Sosman, J A; Kirkwood, J M; Eggermont, A M M; Dreno, B; Nolop, K; Li, J; Nelson, B; Hou, J; Lee, R J; Flaherty, K T; McArthur, A G (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England Journal of Medicine, 364(26):2507-2516.

Bottomley, A; Coens, C; Suciu, S; Santinami, M; Kruit, W; Testori, A; Marsden, J; Punt, C; Salès, F; Gore, M; Mackie, R; Kusic, Z; Dummer, R; Patel, P; Schadendorf, D; Spatz, A; Keilholz, U; Eggermont, A (2009). Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. Journal of Clinical Oncology, 27(18):2916-2923.

Eggermont, A M M; Suciu, S; Santinami, M; Testori, A; Kruit, W H J; Marsden, J; Punt, C J A; Salès, F; Gore, M; Mackie, R; Kusic, Z; Dummer, R; Hauschild, A; Musat, E; Spatz, A; Keilholz, U (2008). Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet, 372(9633):117-126.

This list was generated on Wed Jul 26 11:50:37 2017 CEST.